ALAMAST Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Alamast, and what generic alternatives are available?
Alamast is a drug marketed by Santen and is included in one NDA.
The generic ingredient in ALAMAST is pemirolast potassium. There is one drug master file entry for this compound. Additional details are available on the pemirolast potassium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ALAMAST?
- What are the global sales for ALAMAST?
- What is Average Wholesale Price for ALAMAST?
Summary for ALAMAST
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 54 |
| Patent Applications: | 1,210 |
| DailyMed Link: | ALAMAST at DailyMed |
US Patents and Regulatory Information for ALAMAST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Santen | ALAMAST | pemirolast potassium | SOLUTION/DROPS;OPHTHALMIC | 021079-001 | Sep 24, 1999 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ALAMAST
See the table below for patents covering ALAMAST around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2905689 | ⤷ Start Trial | |
| Australia | 610979 | ⤷ Start Trial | |
| Germany | 3882042 | ⤷ Start Trial | |
| Denmark | 418889 | ⤷ Start Trial | |
| European Patent Office | 0348527 | ANTIALLERGIC EYE DROP | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |

